



Radius Health, Inc.  
Investor Relations Department  
950 Winter St, North Building 1st Floor  
North Building 1st Floor  
Waltham, MA 02451  
United States

[Visit IR website](#)  
[Sign-up for Email alerts](#)

#### NASDAQ: RDUS

Last Trade:	35.80
Trade Time:	1:37 PM ET Aug 17, 2017
Change:	-0.63 <span style="color: red;">▼</span> (-1.729%)
Day Range	35.75 - 36.96
52-Week Range	31.58 - 59.22
Volume	473,134

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical ... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Aug 10, 2017*  
[New National Survey Reveals 82 Percent of Postmenopausal Women Miss Critical Connection Between Osteoporosis and Bone Fractures](#)
- Aug 8, 2017*  
[Radius Health Announces Pricing of \\$300 Million of 3.00% Convertible Senior Notes due 2024](#)
- Aug 7, 2017*  
[Radius Health Announces Proposed Public Offering of \\$300 Million of Convertible Senior Notes due 2024](#)
- Aug 3, 2017*  
[Radius Health Reports Second Quarter 2017 Financial and Operating Results and Provides Business Update](#)
- Jul 21, 2017*  
[Radius Health Announces that the Committee for Medicinal Products for Human Use \(CHMP\) Has Issued a Second Day-180 List of Outstanding Issues in its Regulatory Review of Eladynos™ \(Abaloparatide-SC\), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture](#)

## Financials [\[ View all \]](#)

- [Second Quarter Financial Results](#)
- Feb 24, 2017*  
[Annual Report \(10-K\)](#)
- Apr 21, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 2, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*  
[Quarterly Report \(10-Q\)](#)